ArticleAdvanced science (Weinheim, Baden-Wurttemberg, Germany)2023
In Situ Vaccination with Mitochondria-Targeting Immunogenic Death Inducer Elicits CD8
Article in Advanced science (Weinheim, Baden-Wurttemberg, Germany), 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 33 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
33 citing papers in PubMed, 34 citations in OpenAlex.
- Multifunctional biohybrid nanoplatform interferes electron transport chain amplifying mitochondrial metabolism-mediated anti-tumor therapy.Materials today. Bio · 2026Article
- Programmable DNAzyme nanocatalysts orchestrate redox-immune coupling for time-gated cancer immunomodulation.Journal of nanobiotechnology · 2026Article
- Astragalus Polysaccharides Induce Immunogenic Cell Death in Melanoma: A Mechanism Mediated by cGAS/STING Activation via Intratumoral Microbiota Modulation.Cancer medicine · 2026Article
- pH-responsive CaCOiScience · 2026Article
- Decoding the Sphingolipid Landscape of Clear Cell Renal Cell Carcinoma: A Single-Cell-Guided Prognostic Model Built With 101 Machine Learning.Human mutation · 2026Article
- Mitochondria-targeted strategies in cancer radiotherapy: from ROS regulation to immunogenic cell death.Frontiers in cell and developmental biology · 2026Review
- Emerging Strategies for Antitumor Immunotherapy and Antiviral Defense Through the cGAS-STING Pathway.International journal of nanomedicine · 2026Review
- The application of nanotechnology in regulating mitochondrial function in tumor microenvironment for cancer therapy.Theranostics · 2026Review
- Mitochondria: from powerhouses of cells to hubs in antitumor immunity.Frontiers in immunology · 2026Review
- Mitochondria-Targeted Nanoformulations: New Therapeutic Strategies and Opportunities for Cancer Immunotherapy.Current drug targets · 2026Review
- A smart amphiphilic nanoplatform amplifies ROS-mediated immunogenic cell death to suppress bladder cancer growth and metastasis.Journal of nanobiotechnology · 2025Article
- Mitochondria-targeted MXene@MnOBioactive materials · 2025Article
- Inhibition of DDX3 modulates immune signaling in aggressive breast cancers.Cancer letters · 2025Article
- Sono-triggered endoplasmic reticulum-targeted ROS burst silencing CD300ld to alleviate polymorphonuclear myeloid-derived suppressor cells for breast cancer treatment.Journal of nanobiotechnology · 2025Article
- NeoadjuvantCancers · 2025Review
- Mechanisms for fibrate lipid-lowering drugs in enhancing bladder cancer immunotherapy by inhibiting CD276 expression.BMC cancer · 2025Article
- Co-delivery paclitaxel and IR783 as nanoparticles for potentiated chemo-photothermal-immunotherapy of triple-negative breast cancer.Materials today. Bio · 2025Article
- The cGAS-STING pathway: a dual regulator of immune response in cancer and therapeutic implications.Journal of translational medicine · 2025Review
- Celastrol loaded nanocomplex for painless tumor therapy via YAP inhibition.Scientific reports · 2025Article
- Mitochondria-Targeting Type-I Photodynamic Therapy Based on Phenothiazine for Realizing Enhanced Immunogenic Cancer Cell Death via Mitochondrial Oxidative Stress.International journal of nanomedicine · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors at 2 institutions in 1 country.
Funding
Abstract
In situ vaccination can elicit systemic antitumor immunity to potentiate immune checkpoint blockade (ICB) in poorly immunogenic tumors. Herein, an immunogenic cell death (ICD) inducer for in situ vaccination, which is based on a mitochondria-targeting modification of fenofibric acid (FFa), a lipid-lowering drug with potential inhibitory efficacy of respiratory complex I is developed. Mitochondria-targeting FFa (Mito-FFa) inhibits complex I efficiently and increases mitochondrial ROS (mtROS) generation, which further triggers endoplasmic reticulum (ER) stress with unprecedented calreticulin (CRT) exposure on tumor cellular membranes. Moreover, the generated mtROS also oxidizes mitochondrial DNA (mtDNA) and promotes it leakage into the cytoplasm for cGAS-STING-dependent type I interferon (IFN-I) secretion. The synchronous CRT exposure and IFN-I secretion successively improve the uptake of tumor antigens, maturation of dendritic cells (DCs) and cross-priming of CD8
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.